Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents.

Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM.

JAMA. 2013 Oct 9;310(14):1462-72. doi: 10.1001/jama.2013.278787. Erratum in: JAMA. 2014 Feb 5;311(5):528.

PMID:
24101118
2.

The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting.

Holcomb CN, Graham LA, Richman JS, Rhyne RR, Itani KM, Maddox TM, Hawn MT.

J Am Coll Cardiol. 2014 Dec 30;64(25):2730-9. doi: 10.1016/j.jacc.2014.09.072.

3.

Improved adverse postoperative outcomes with revised American College of Cardiology/American Heart Association guidelines for patients with cardiac stents.

Graham LA, Singletary BA, Richman JS, Maddox TM, Itani KM, Hawn MT.

JAMA Surg. 2014 Nov;149(11):1113-20. doi: 10.1001/jamasurg.2014.2044.

PMID:
25188466
4.

The incidence and timing of noncardiac surgery after cardiac stent implantation.

Hawn MT, Graham LA, Richman JR, Itani KM, Plomondon ME, Altom LK, Henderson WG, Bryson CL, Maddox TM.

J Am Coll Surg. 2012 Apr;214(4):658-66; discussion 666-7. doi: 10.1016/j.jamcollsurg.2011.12.011. Epub 2012 Feb 16.

PMID:
22341201
5.

Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry.

Berger PB, Kleiman NS, Pencina MJ, Hsieh WH, Steinhubl SR, Jeremias A, Sonel A, Browne K, Barseness G, Cohen DJ; EVENT Investigators.

JACC Cardiovasc Interv. 2010 Sep;3(9):920-7. doi: 10.1016/j.jcin.2010.03.021.

6.

Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.

Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.

Catheter Cardiovasc Interv. 2013 May;81(6):E237-44. doi: 10.1002/ccd.24513. Epub 2012 Nov 14.

PMID:
22707383
7.

Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents.

van Kuijk JP, Flu WJ, Schouten O, Hoeks SE, Schenkeveld L, de Jaegere PP, Bax JJ, van Domburg RT, Serruys PW, Poldermans D.

Am J Cardiol. 2009 Nov 1;104(9):1229-34. doi: 10.1016/j.amjcard.2009.06.038.

PMID:
19840567
8.

Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).

Holmvang L, Kelbæk H, Kaltoft A, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S.

JACC Cardiovasc Interv. 2013 Jun;6(6):548-53. doi: 10.1016/j.jcin.2012.12.129. Epub 2013 May 15.

9.

Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.

Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.

Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056. Epub 2013 Nov 11.

10.

Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery.

Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE; Scottish Coronary Revascularisation Register Steering Committee.

Circ Cardiovasc Interv. 2010 Jun 1;3(3):236-42. doi: 10.1161/CIRCINTERVENTIONS.109.934703. Epub 2010 May 4.

11.
12.

3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.

De Felice F, Fiorilli R, Parma A, Nazzaro M, Musto C, Sbraga F, Caferri G, Violini R.

JACC Cardiovasc Interv. 2009 Dec;2(12):1260-5. doi: 10.1016/j.jcin.2009.09.013.

13.

Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.

Almalla M, Pross V, Marx N, Hoffmann R.

Coron Artery Dis. 2012 Nov;23(7):492-6.

PMID:
22990414
14.

Cardiac events after non-cardiac surgery in patients with previous coronary intervention in the drug-eluting stent era.

Bolad IA, Alqaqa'a A, Khan B, Srivastav SK, von der Lohe E, Sadanandan S, Breall JA.

J Invasive Cardiol. 2011 Jul;23(7):283-6.

15.

Association of Coronary Stent Indication With Postoperative Outcomes Following Noncardiac Surgery.

Holcomb CN, Hollis RH, Graham LA, Richman JS, Valle JA, Itani KM, Maddox TM, Hawn MT.

JAMA Surg. 2015 Dec 30:1-8. doi: 10.1001/jamasurg.2015.4545. [Epub ahead of print]

PMID:
26720292
16.

Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registry.

Gilis-Siek N, Fijalkowski M, Jaguszewski M, Targonski R, Strozyk A, Cackowska M, Masiewicz E, Skarzynski P, Burakowski S, Chmielecki M, Lewicki L, Dubaniewicz W, Gruchala M, Ciecwierz D, Rynkiewicz A.

J Invasive Cardiol. 2013 Nov;25(11):567-72.

17.

Major adverse cardiac events in patients with hepatitis C infection treated with bare-metal versus drug-eluting stents.

Palaniswamy C, Aronow WS, Sukhija R, Chugh T, Ramdeen N, Kalapatapu K, Weiss MB, Pucillo AL, Monsen CE.

Clin Cardiol. 2010 Jun;33(6):367-70. doi: 10.1002/clc.20764.

18.

Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.

Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ.

JACC Cardiovasc Interv. 2008 Oct;1(5):494-503. doi: 10.1016/j.jcin.2008.06.011.

19.

The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter.

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.

20.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2015 Jun 2;313(21):2185.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk